Abstract | OBJECTIVE: METHODS: Utilizing the 1991-2010 population-based, parkinsonism-incident cohort of Olmsted County, MN (n = 669), accessed via the Rochester Epidemiology Project, we identified patients with PD and abstracted levodopa-related dyskinesia information. RESULTS: Of 309 patients with PD (46.2% with parkinsonisms), 279 (90.3%) received levodopa. Most (230/279; 82.4%) had been treated by a Mayo Clinic neurologist. Median age of the 309 patients with PD at the time of diagnosis was 74.1 years (range 33.1-97.8 years). Median-age levodopa initiation in this cohort was 75 years (range 37-98 years), and median-duration levodopa treatment was 6 years (range 2 months to 19.8 years). Dyskinesia was documented in 84 of 279 patients (30.1%). Median time from levodopa initiation to dyskinesia onset was 4 years (range 2 months to 20 years); those with dyskinesia (65.5%; 55/84) developed it within 5 years of levodopa initiation (9 within the first year). Dyskinesia was mild in 57/84 (67.9%), moderate in 16/84 (19.1%), and severe in 9/84 (10.7%); severity was not reported in 2 cases. Dyskinesia severity led to levodopa adjustments or amantadine initiation in 60.7% (51/84 of those with dyskinesia), with improvement in 23/51 (45.1%). Thirteen patients with dyskinesia underwent deep brain stimulation, reporting marked improvement. Postmortem examination confirmed Lewy body disease in 7 autopsied cases. CONCLUSIONS:
|
Authors | Pierpaolo Turcano, Michelle M Mielke, James H Bower, Joseph E Parisi, Jeremy K Cutsforth-Gregory, J Eric Ahlskog, Rodolfo Savica |
Journal | Neurology
(Neurology)
Vol. 91
Issue 24
Pg. e2238-e2243
(12 11 2018)
ISSN: 1526-632X [Electronic] United States |
PMID | 30404780
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | © 2018 American Academy of Neurology. |
Chemical References |
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Cohort Studies
- Dyskinesia, Drug-Induced
(epidemiology)
- Female
- Humans
- Levodopa
(adverse effects)
- Male
- Middle Aged
- Parkinson Disease
(complications, drug therapy, epidemiology)
- Severity of Illness Index
|